Articles related to VALVULAR HEART DISEASE (VHD)
The New England Journal of Medicine
Transcatheter Repair for Patients with Tricuspid Regurgitation
The study in question presents a prospective randomized trial that evaluated the efficacy and safety of percutaneous tricuspid transcatheter edge-to-edge repair (TEER) in patients with severe tricuspid regurgitation. Conducted across 65 centers in North America and Europe, 350 patients were randomized into two equal groups, with one group undergoing TEER and the other receiving conventional medical therapy. The primary composite endpoint encompassed factors such as all-cause mortality or tricuspid valve surgery, heart failure hospitalization, and improvement in quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Also evaluated were the severity of tricuspid regurgitation and the safety profile of TEER. The trial concluded with results favoring the TEER group (win ratio, 1.48; 95% CI, 1.06-2.13; P=0.02), although rates of death, tricuspid-valve surgery, and heart failure hospitalization showed no significant difference between the two groups. The TEER group exhibited a marked improvement in KCCQ scores compared to the control group (mean change 12.3±1.8 vs. 0.6±1.8; P<0.001) and a significant reduction in the severity of tricuspid regurgitation at the 30-day mark (87.0% TEER group vs. 4.8% control group with tricuspid regurgitation of no greater than moderate severity; P<0.001). The safety profile for TEER was reassuring, with 98.3% of patients […]
Cardiology May 22nd 2023
Apixaban vs. Rivaroxaban in Patients with Atrial Fibrillation and Valvular Heart Disease
When compared with rivaroxaban in a propensity score–matched cohort of 19,894 patients, apixaban was associated with an approximately 50% lower rate of ischemic stroke or systemic embolism and bleeding compared to rivaroxaban.
Cardiology October 26th 2022